Tg Therapeutics (TGTX) Income from Continuing Operations (2011 - 2026)
Tg Therapeutics (TGTX) reported Income from Continuing Operations of $7.73 million for Q2 2026, down 72.6% from $28.19 million a year earlier and down 60.9% from the prior quarter.
Powered by 
Analysis
Tg Therapeutics (TGTX) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Tg Therapeutics' Income from Continuing Operations came in at $441.44 million, up 630.2% year-over-year; for FY2025, it came in at $447.18 million.
- By year, Income from Continuing Operations came in at $23.38 million in FY2024 (+84.5%), $12.67 million in FY2023, -$223.81 million in FY2022 and -$348.1 million in FY2021.
- The Q2 2026 figure ranks as the lowest quarterly Income from Continuing Operations since Q1 2025.
- Year over year, Income from Continuing Operations gained in two of the last five quarters, with growth averaging 86.0%.
- Per Business Quant data, the three quarters before Q2 2026 came in at $19.76 million (Q1 2026), $23.04 million (Q4 2025) and $390.91 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,167.12 Bn | 1,135.70 Bn | 19.71 Bn | 7.10 Bn |
| 2 | Johnson & Johnson | 647.48 Bn | 567.35 Bn | 17.30 Bn | 210.00 Mn |
| 3 | AbbVie | 502.73 Bn | 475.84 Bn | 12.70 Bn | 3.62 Bn |
| 4 | Merck | 363.86 Bn | 318.23 Bn | 12.21 Bn | -1.34 Bn |
| 5 | Novartis Ag | 303.31 Bn | 267.30 Bn | 11.24 Bn | 3.26 Bn |
| 6 | Astrazeneca | 269.08 Bn | 242.77 Bn | 12.86 Bn | 2.51 Bn |
| 7 | Amgen | 242.07 Bn | 197.46 Bn | 7.24 Bn | 2.38 Bn |
| 8 | Gilead Sciences | 194.93 Bn | 169.12 Bn | 6.22 Bn | -10.50 Bn |
| 9 | Pfizer | 172.42 Bn | 119.07 Bn | 10.94 Bn | -246.00 Mn |
| 10 | Tg Therapeutics | 7.50 Bn | 6.89 Bn | 199.14 Mn | 7.73 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.73 Mn |
| Mar 31, 2026 | 19.76 Mn |
| Dec 31, 2025 | 23.04 Mn |
| Sep 30, 2025 | 390.91 Mn |
| Jun 30, 2025 | 28.19 Mn |
| Mar 31, 2025 | 5.06 Mn |
| Dec 31, 2024 | 23.34 Mn |
| Sep 30, 2024 | 3.87 Mn |
| Jun 30, 2024 | 6.88 Mn |
| Mar 31, 2024 | -10.71 Mn |
| Dec 31, 2023 | -14.42 Mn |
| Sep 30, 2023 | 113.93 Mn |
| Jun 30, 2023 | -47.61 Mn |
| Mar 31, 2023 | -39.23 Mn |
| Dec 31, 2022 | -80.40 Mn |
| Sep 30, 2022 | -36.61 Mn |
| Jun 30, 2022 | -41.96 Mn |
| Mar 31, 2022 | -76.94 Mn |
| Dec 31, 2021 | -98.63 Mn |
| Sep 30, 2021 | -86.17 Mn |
API Access
Tg Therapeutics Income from Continuing Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=TGTX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-continuing-operations", "ticker": "TGTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=TGTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();